Topamax may have role in bipolar disorder

6 December 2001

Researchers from the University of Barcelona, Spain, presented resultswhich suggest that Janssen-Ortho's anti-epiletic drug Topamax (topiramate), could be used to improve the manic symptoms of bipolar disorder, at the International Forum on Mood and Anxiety Disorders, in Monte Carlo. Of the 61 adults who particpated in the 12-week study, 70% experienced an improvement of 50% or greater in their scores in the Young Mania Rating Scale. In addition, 41% met the criteria for remission.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight